Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 15;226(Suppl 2):S143-S147.
doi: 10.1093/infdis/jiac211.

The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis

Eric A F Simões  1   2
Affiliations

The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis

Eric A F Simões. J Infect Dis. .
No abstract available

Keywords: costs; epidemiology; hospitalization; mortality.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. E. A. F. S. reports the following: grants and consulting fees to the institution from Merck & Co. and Pfizer Inc; grants to the institution from Astra Zeneca Inc., Roche Pharmaceuticals, and Johnson and Johnson; consulting fees to the institution from Sanofi, Cidara Therapeutics, Adiago Therapeutics Inc, and Nuance Pharmaceuticals; manuscript writing support from Sanofi and Astra Zeneca Inc.; support for attending a meeting at Astra Zeneca Inc. and participation on a Data and Safety Monitoring Board from Abbvie Inc., GlaxoSmithKline plc, and the Bill & Melinda Gates Foundation, all outside the submitted work. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. Simoes EA. Respiratory syncytial virus infection. Lancet 1999; 354:847–52. doi:10.1016/s0140-6736(99)80040-3. - PubMed
    1. McLellan JS, Chen M, Joyce MG, et al. . Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592–8. doi:10.1126/science.1243283. - PMC - PubMed
    1. Zhu Q, McLellan JS, Kallewaard NL, et al. . A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 2017; 9. pii: 9/388/eaaj1928 doi:10.1126/scitranslmed.aaj1928. - PubMed
    1. Tang A, Chen Z, Cox KS, et al. . A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun 2019; 10:4153; doi:10.1038/s41467-019-12137-1. - PMC - PubMed
    1. Safety, tolerability, and pharmacokinetics of RSV monoclonal antibody RSM01 in healthy adults. Available at: https://clinicaltrials.gov/ct2/show/NCT05118386. Accessed 7 May 2022.